Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Kids' diarrhea: drug plus fluids tested

NCT ID NCT07285785

First seen Jan 10, 2026 · Last updated Jun 19, 2026 · Updated 18 times

Summary

This study tests how the drug rifaximin (Xifaxan) works in children aged 6 to 11 with acute diarrhea likely caused by bacteria. Half the children get the drug plus oral rehydration therapy, the other half get rehydration alone. Researchers want to see if adding the drug helps diarrhea resolve faster and is safe for kids.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Direct Helpers

    NOT_YET_RECRUITING

    Hialeah, Florida, 33012, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • LinQ Research

    RECRUITING

    Rosharon, Texas, 77583, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Oceane7 Medical & Research Center, Inc

    RECRUITING

    Miami, Florida, 33144, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SouthCoast Research Center

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tekton Research

    RECRUITING

    Richmond, Virginia, 23233, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rifaximin (Xifaxan) 200 mg tablet

What this could lead to

If it works, this could provide a new treatment option for bacterial diarrhea in children, shortening illness and reducing symptoms.

What could go wrong

This is a small Phase 4 study with only 54 children, so results may not apply broadly. Rifaximin may not speed recovery over rehydration alone, and side effects are possible.

Conditions

The condition(s) this trial relates to.

acute diarrhea bacterial infectious disease diarrheal disease gastroenteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.